Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio, +7

Journal of Cancer Research and Clinical Oncology

MedicineImmunologyMulti-institutional AnalysisImmune Checkpoint InhibitorBronchial Neoplasm +6

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Matteo Canale, Elisabetta Petracci, Angelo Delmonte, +14

Journal of Clinical Medicine

Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer

Martina Mandarano, Elena Orecchini, Guido Bellezza, +9

International Journal of Molecular Sciences

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer

Paola Ulivi, Elisabetta Petracci, Giorgia Marisi, +13

Journal of Clinical Medicine

ImmunologyPathologyTumor BiologyOncologyMolecular Diagnostics +16

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

Biagio Ricciuti, Carlo Genova, Maria Bassanelli, +8

Clinical Lung Cancer

OncologyCancer ManagementImmune Checkpoint InhibitorCancer TreatmentMedicine +2

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis

Rita Chiari, Giulio Metro, Daniela Iacono, +12

Lung Cancer

Multicenter AnalysisMedicinePathologyBronchial NeoplasmImmune Checkpoint Inhibitor +7

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Giulio Metro, Sara Baglivo, Guido Bellezza, +20

Genes

Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer

Sara Baglivo, Vienna Ludovini, Angelo Sidoni, +7

Mayo Clinic Proceedings

Egfr -T790m MutationAcquired ResistanceOncogenic AgentMedicinePathology +7

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients

Vienna Ludovini, Fortunato Bianconi, Annamaria Siggillino, +14

Genes

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

Sara Baglivo, Vienna Ludovini, Riccardo Moretti, +4

Oncology and Therapy

ImmunologyImmunoeditingRet RearrangementImmunotherapeuticsImmunotherapy +20